MedPath

Efficacy and Safety of Valsartan and Aliskiren Combination Therapy in Patients with Diabetic Nephropathy and Hypertensio

Not Applicable
Conditions
Type 2 diabetes with nephropathy and hypertension
Registration Number
JPRN-UMIN000003741
Lead Sponsor
Kansai Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
80
Inclusion Criteria

Not provided

Exclusion Criteria

1)Taking corticosteroid 2)Secondary hypertension or maliganant hypertension 3)Acute myocardial infarction within 24 weeks 4)Stroke within 12 weeks 5)Severe ventricular tachyarrhythmia or advanced AV block 6)Cardiogenic shock 7)Bilateral renal artery stenosis 8)Sever liver dysfunction 9)Severe hematopoietic disorder or carcinoma 10)Type 1 diabetes 11)Taking cyclosporine A 12)Pregnancy 13)Drug allergy 14) not qualified

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath